C

CG Oncology Inc
NASDAQ:CGON

Watchlist Manager
CG Oncology Inc
NASDAQ:CGON
Watchlist
Price: 41.79 USD 0.65% Market Closed
Market Cap: 3.4B USD

During the last 3 months CG Oncology Inc insiders have not bought any shares, and sold 344.4k USD worth of shares. The stock price has increased by 10% over this period (open performance analysis).

The last transaction was made on Nov 17, 2025 by Post Leonard E , who sold 41.4k USD worth of CGON shares.

Last Transactions:
Post Leonard E
$-41.4k
Post Leonard E
$-43.3k
Mulay James
$-259.7k
Post Leonard E
$-200.5k
Mulay James
$-499.9k
Mulay James
$-139.4k
Mulay James
$-745.6k
Post Leonard E
$-35.1k
Liu Brian Guan-Chyun
$+50m
Mulay James
$-376.1k
Post Leonard E
$-28k
Song Hong Fang
$-1.9m
Post Leonard E
$-56k
Post Leonard E
$-28k
Post Leonard E
$-30.8k
Post Leonard E
$-28k
Post Leonard E
$-28.6k
Post Leonard E
$-29.7k
Post Leonard E
$-28.8k
Song Hong Fang
$-19.6m
Post Leonard E
$-25.8k
Song Hong Fang
$-15m
View All Transactions

During the last 3 months CG Oncology Inc insiders have not bought any shares, and sold 344.4k USD worth of shares. The stock price has increased by 10% over this period (open performance analysis).

The last transaction was made on Nov 17, 2025 by Post Leonard E , who sold 41.4k USD worth of CGON shares.

Sold
0-3
months
344.4k USD
2
3-6
months
4m USD
3
6-9
months
58.8k USD
1
9-12
months
86.3k USD
1
Bought
0-3
months
0
0 USD
3-6
months
1
50m USD
6-9
months
0
0 USD
9-12
months
0
0 USD

CG Oncology Inc
Insider Trading Chart

CG Oncology Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

CG Oncology Inc
Last Insider Transactions

Global
Insiders Monitor

CG Oncology Inc
Glance View

Market Cap
3.3B USD
Industry
Biotechnology

CG Oncology Inc. is navigating the turbulent waters of biotechnology with a laser focus on the treatment of bladder cancer. Rooted deeply in the realm of oncolytic immunotherapy, the company harnesses the power of genetically modified viruses to selectively infect and destroy cancer cells. Their flagship product, CG0070, is at the heart of this endeavor, utilizing a modified adenovirus that targets tumors after traditional treatments have failed or when they present a significant clinical challenge. This targeted approach not only aims to disrupt tumor growth directly but also to stimulate a broader immune response, turning the patient's own defenses against the malignant invaders. Commercial success in this niche is predicated on the ability to navigate a highly regulated space with lengthy clinical trials and significant investment in research and development. CG Oncology makes money by progressing its therapies through these clinical development stages, eventually securing regulatory approvals. The ultimate goal is to partner with larger pharmaceutical companies or independently bring their treatments to market, capitalizing on licensing agreements, sales, and milestone payments. This reflects a strategy commonly seen in the biotech sector, where innovation and partnerships drive revenue, turning cutting-edge science into viable, life-extending products for patients and profitable ventures for investors.

CGON Intrinsic Value
31.79 USD
Overvaluation 24%
Intrinsic Value
Price
C

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top